HomeProductsBioactive CompoundsCytoskeletonFAKDefactinib
Chemical structure of CAS 1073154-85-4

Defactinib

CAS No.1073154-85-4
MDL No.MFCD25977806
MFC20H21F3N8O3S
MW510.50
InChI KeyFWLMVFUGMHIOAA-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1073154-85-4
Product NameDefactinib

Biological Targets

PTK2·PTK2B

Associated Conditions

pancreatic ductal adenocarcinoma·pancreatic carcinoma·melanoma·malignant pleural mesothelioma·thyroid carcinoma·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.

The Prostate • Vol. 78, Issue 4 • 2018
PMID: 29314097DOI: 10.1002/pros.23476

The target landscape of clinical kinase drugs.

Science (New York, N.Y.) • Vol. 358, Issue 6367 • 2017
PMID: 29191878PMC: PMC6542668DOI: 10.1126/science.aan4368

A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors.

Cancer chemotherapy and pharmacology • Vol. 77, Issue 5 • 2016
PMID: 27025608PMC: PMC4844649DOI: 10.1007/s00280-016-3010-1

A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.

Investigational new drugs • Vol. 33, Issue 5 • 2015
PMID: 26334219DOI: 10.1007/s10637-015-0282-y

Documentation

Similar Products